Insider filing · VERA

Patrick G Enright bought $5.3M of Vera Therapeutics (VERA)

Executed Jun 23 2025, disclosed Jun 25 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Jun 25 2025), the stock returned -3.1% (delay-adjusted); from the execution session (Jun 23 2025), +7.6%. Derived: entry at the session's open, exit at the close 20 sessions later.

PE Patrick G Enright Director profile →

Patrick G Enright (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Vera Therapeutics, Inc. (VERA). Across 3 priced purchase filings, the average 21-session return was +18.6% from execution and +20.1% from disclosure (delay-adjusted; derived). The largest single filing was $18.3M of MANE (1,075,000 sh across 2 lots, as filed), executed Feb 5.

VERA Vera Therapeutics, Inc. VERA · Healthcare · 30 filings in 24 months ticker →

Healthcare · Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatme…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→